Metformin Aurobindo

Metformin Hydrochloride, the active ingredient in Metformin Aurobindo, is a biguanide presented as a unknown/unknown for oral use. It lowers elevated blood glucose levels in adults with type 2 diabetes mellitus by decreasing hepatic glucose production, reducing intestinal glucose absorption, and enhancing peripheral insulin sensitivity.

GNH USA supplies Metformin Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines across global markets. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity.

Metformin Aurobindo, a biguanide antidiabetic, is employed to manage hyperglycemia within the type 2 diabetes therapeutic pathway. - Type 2 diabetes mellitus: improves glycemic control in adults with type 2 diabetes. - Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes when used under medical supervision. - Polycystic ovary syndrome (PCOS): reduces insulin resistance and may improve menstrual regularity in women with PCOS.

Metformin Aurobindo may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or flatulence. - Diarrhea: loose, watery stools. - Metallic taste: transient metallic sensation. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal accumulation of lactate. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Vitamin B12 deficiency: long‑term use may lower B12 levels.

When prescribing Metformin Aurobindo, clinicians should observe several precautionary measures to minimize risk. - Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter. - Hepatic function monitoring: check liver enzymes, especially in patients with existing liver disease. - Lactic acidosis risk: avoid use in patients with conditions predisposing to hypoxia or severe infection. - Pregnancy and lactation: consider risks and benefits; use only if clearly needed. - Drug interaction vigilance: review concomitant medications that may increase metformin levels. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Metformin Aurobindo can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol excess: potentiates lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may impair renal function, enhancing metformin accumulation. - Beta‑blockers: can mask hypoglycemia symptoms when combined with insulin secretagogues. - NSAIDs: may reduce renal perfusion, affecting metformin clearance. - Sulfonylureas: increase risk of hypoglycemia when used together.